Aethlon Medical, Inc. Overview
Pro stress-test →Aethlon Medical is a clinical-stage medical device company headquartered in San Diego, California, advancing the Hemopurifier to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids. The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived EVs from circulation, used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin.
Strategic Profile
Pro stress-test →The Hemopurifier holds a U.S. Food and Drug Breakthrough Device designation for treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy. The company advanced to the final cohort in its oncology clinical trial in March 2026 following positive Data Safety Monitoring Board review, with focus on patients receiving anti-PD-1 immunotherapy.
Competitive Landscape
Pro stress-test →Aethlon competes in the immunotherapy resistance space against companies developing alternative approaches to enhance response to checkpoint inhibitors. Direct competitors include extracellular vesicle-targeting therapies and combination immunotherapy approaches. The Hemopurifier's unique blood filtration mechanism provides differentiation versus small-molecule or antibody-based approaches.
Industry Context
Aethlon Medical, Inc. operates in Medical Device / Immunotherapy Enhancement.
Key facts
Headquarters: San Diego, US